Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 7,588 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Population Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

NCT04128007
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Roflumilast foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
31
States / cities
Rogers, Arkansas • Fremont, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 29, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

NCT03329092
View directory record Official record
Conditions
Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia
Interventions
ATM-AVI, MTZ, MER, COL
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Tucson, Arizona • Torrance, California • Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 29, 2026, 6:07 AM EDT
Withdrawn Not applicable Interventional

Study of Hemostatic Efficacy of the HemCon Dental Dressing in a Population Treated With Anticoagulant Medications

NCT00707564
View directory record Official record
Conditions
Tooth Extractions
Interventions
HemCon Dental Dressing, Gauze with pressure
Device
Lead sponsor
HemCon Medical Technologies, Inc
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Milwaukie, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 29, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter Assessment of ALD403 in Chronic Migraine

NCT02275117
View directory record Official record
Conditions
Migraine Disorders
Interventions
ALD403, Placebo
Biological
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
82
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 29, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

NCT01728324
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
31
States / cities
North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 29, 2026, 6:07 AM EDT
Terminated No phase listed Observational

Biventricular Pacing in the Pediatric Population

NCT00267423
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 4, 2007 · Synced Oct 29, 2026, 6:07 AM EDT
Completed No phase listed Observational

Pharmacogenetic Variation: Factors That May Affect the Efficacy and Safety of Medical Marijuana

NCT04083261
View directory record Official record
Conditions
New York Medical Marijuana Program Qualifying Conditions
Interventions
DNA Genotek Oragene 600
Other
Lead sponsor
Columbia Care Inc.
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 29, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

Study of FX006 in Patients With Osteoarthritis of the Knee

NCT01487161
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
FX006, TCA IR
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Tucson, Arizona • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 29, 2026, 6:07 AM EDT
Withdrawn Not applicable Interventional

Pre-op Bowel Prep Before Abdominal Surgery

NCT01512394
View directory record Official record
Conditions
Pre-operative Bowel Prep
Interventions
standard bowel prep, no bowel prep
Procedure
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
3 Months to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 29, 2026, 6:07 AM EDT
Completed Phase 3 Interventional

Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder

NCT00113594
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Olanzapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
15
States / cities
Cerritos, California • National City, California • Poway, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 29, 2026, 6:07 AM EDT
Terminated Phase 3 Interventional Results available

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

NCT01059682
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Dalcetrapib, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
41
States / cities
Los Angeles, California • Torrance, California • Boulder, Colorado + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 29, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

NCT00487942
View directory record Official record
Conditions
Schizophrenia
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
12
States / cities
Garden Grove, California • National City, California • Paramount, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 29, 2026, 6:07 AM EDT
Active, not recruiting Not applicable Interventional

TReatment of Pulmonary Hypertension Group II Study

NCT03611270
View directory record Official record
Conditions
Pulmonary Hypertension (PH) Due to Left Heart Disease
Interventions
Pulmonary Denervation
Device
Lead sponsor
SoniVie Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 29, 2026, 6:07 AM EDT
Active, not recruiting No phase listed Observational

Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group

NCT01117168
View directory record Official record
Conditions
Pediatric Cancer, Leukemia, Sarcoma, Brain Tumors
Interventions
Not listed
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
57,816 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 29, 2026, 6:07 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Improving Show Rates in Dental Care Settings Serving Underserved Populations

NCT06581250
View directory record Official record
Conditions
Dental Care
Interventions
Reminder Messages, Walk-in Visits, Motivation-enhanced Communication
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

MPC-004 for the Treatment of an Acute Gout Flare

NCT00506883
View directory record Official record
Conditions
Gout
Interventions
High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
83
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 29, 2026, 6:07 AM EDT
Completed Phase 3 Interventional

Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study

NCT00001217
View directory record Official record
Conditions
Osteosarcoma
Interventions
pre-surgical chemotherapy
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 6:07 AM EDT
Completed Phase 4 Interventional Results available

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT01957150
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate/Vilanterol, Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
17
States / cities
Jasper, Alabama • Phoenix, Arizona • Fort Lauderdale, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 29, 2026, 6:07 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Phoenix, Arizona • Imperial, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01431274
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
2,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Jasper, Alabama • Mobile, Alabama • Boulder, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 29, 2026, 6:07 AM EDT
Completed Phase 3 Interventional

Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.

NCT00380224
View directory record Official record
Conditions
Schizophrenia
Interventions
bifeprunox, olanzapine
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
67
States / cities
Little Rock, Arkansas • Anaheim, California • Boynton Beach, California + 55 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 29, 2026, 6:07 AM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

NCT01610596
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Halobetasol Propionate Lotion 0.05%, Placebo
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 29, 2026, 6:07 AM EDT
Not listed Phase 2 Interventional

Phase 2a Randomized, Double-Blind Study of Oleoyl-Estrone in Male Morbidly Obese Adults

NCT00449254
View directory record Official record
Conditions
Obesity
Interventions
oleoyl-estrone (MP-101)
Drug
Lead sponsor
Manhattan Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
New York, New York • Dallas, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 5, 2007 · Synced Oct 29, 2026, 6:07 AM EDT
Enrolling by invitation No phase listed Observational

Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)

NCT06280820
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
Baltimore, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 29, 2026, 6:07 AM EDT